GlassScriptPhysician profile
Adel M Sidky
NPI 1235138082
$22,180.12
in general payments reported to CMS, 2019-2025
45 companies · $2,903 in 2025
The $2,903 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,475 · 2020: $2,176 · 2021: $4,427 · 2022: $2,234 · 2023: $2,391 · 2024: $4,574 · 2025: $2,903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,497 · Travel and Lodging: $1,161 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,496.57 |
| Travel and Lodging | $1,161.24 |
| Education | $209.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,672.69 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Cvrx, INC. | $1,824.60 | 2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $1,792.76 | 2019-2025 | Farxiga, Breztri, Brilinta |
| Bayer Healthcare Pharmaceuticals INC. | $1,681.54 | 2021-2025 | |
| Boston Scientific Corporation | $1,624.86 | 2019-2025 | Watchman Flx, Bodyguardian, Watchman Access System |
| Amgen INC. | $1,435.97 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,357.12 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $1,067.91 | 2019-2025 | Verquvo, Capvaxive, Belsomra |
| Novartis Pharmaceuticals Corporation | $839.78 | 2019-2025 | |
| Lilly USA, LLC | $727.28 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $608.73 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $522.85 | 2020-2025 | Nexletol |
| Abbott Laboratories | $509.32 | 2019-2025 | Amplatzer Amulet, Esprit |
| Alnylam Pharmaceuticals INC. | $499.70 | 2022-2025 | Amvuttra, Onpattro |
| Actelion Pharmaceuticals US, INC. | $453.70 | 2019-2025 | Uptravi, Opsumit |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adel Sidky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.